Clinical Trials
7 trialsNCT05101148 2026-05-20
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
Phase 1 Active not recruiting
NCT04590235 2026-05-14
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT04924608 2026-03-23
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT05309668 2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2 Active not recruiting
NCT05825365 2023-08-14
PROTECT
AstraZeneca
Phase 2 Withdrawn
NCT04495127 2023-04-26
Selumetinib Paediatric NF1 Japan Study
AstraZeneca
Phase 1 Completed
NCT03259633 2020-05-01
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
AstraZeneca
Approved for marketing